Torjan Haslerud

903 total citations
24 papers, 668 citations indexed

About

Torjan Haslerud is a scholar working on Epidemiology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Torjan Haslerud has authored 24 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 12 papers in Oncology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Torjan Haslerud's work include Neuroendocrine Tumor Research Advances (11 papers), Lung Cancer Research Studies (11 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Torjan Haslerud is often cited by papers focused on Neuroendocrine Tumor Research Advances (11 papers), Lung Cancer Research Studies (11 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Torjan Haslerud collaborates with scholars based in Germany, Norway and France. Torjan Haslerud's co-authors include Samer Ezziddin, Amir Sabet, Hans‐Jürgen Biersack, Hojjat Ahmadzadehfar, Karin Mayer, Winfried A. Willinek, Amin Sabet, Kai Wilhelm, Ulrich‐Frank Pape and Stefan Guhlke and has published in prestigious journals such as SHILAP Revista de lepidopterología, British Journal of Cancer and Journal of Nuclear Medicine.

In The Last Decade

Torjan Haslerud

21 papers receiving 654 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Torjan Haslerud Germany 12 471 445 353 183 88 24 668
Beth Chasen United States 11 369 0.8× 343 0.8× 261 0.7× 122 0.7× 10 0.1× 19 557
Maria Rinzivillo Italy 20 990 2.1× 961 2.2× 600 1.7× 75 0.4× 13 0.1× 66 1.1k
Marianne E. Pavel Germany 5 564 1.2× 470 1.1× 369 1.0× 256 1.4× 2 0.0× 11 748
Claudia Brogsitter Germany 11 105 0.2× 104 0.2× 57 0.2× 204 1.1× 15 0.2× 35 388
Ana L. Keppke United States 9 125 0.3× 213 0.5× 29 0.1× 152 0.8× 167 1.9× 10 467
Nalan Alan Selçuk Türkiye 11 86 0.2× 99 0.2× 59 0.2× 182 1.0× 5 0.1× 43 342
Pablo Mínguez Gabiña Spain 9 88 0.2× 67 0.2× 35 0.1× 442 2.4× 42 0.5× 24 533
Jan-Paul Esser Netherlands 5 606 1.3× 485 1.1× 422 1.2× 242 1.3× 6 751
Jutta Kappes Germany 13 173 0.4× 260 0.6× 21 0.1× 73 0.4× 11 0.1× 23 414
M. Ciresa Italy 9 68 0.1× 62 0.1× 26 0.1× 114 0.6× 72 0.8× 22 340

Countries citing papers authored by Torjan Haslerud

Since Specialization
Citations

This map shows the geographic impact of Torjan Haslerud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torjan Haslerud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torjan Haslerud more than expected).

Fields of papers citing papers by Torjan Haslerud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torjan Haslerud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torjan Haslerud. The network helps show where Torjan Haslerud may publish in the future.

Co-authorship network of co-authors of Torjan Haslerud

This figure shows the co-authorship network connecting the top 25 collaborators of Torjan Haslerud. A scholar is included among the top collaborators of Torjan Haslerud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torjan Haslerud. Torjan Haslerud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Langer, Seppo W., Anna Sundlöv, Lene Weber Vestermark, et al.. (2023). Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. British Journal of Cancer. 129(12). 1930–1939. 11 indexed citations
3.
Madland, Tor Magne, et al.. (2023). VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia. SHILAP Revista de lepidopterología. 2023. 1–7. 10 indexed citations
4.
Haslerud, Torjan, et al.. (2022). Enhancing PSMA-PET/CT with intravenous contrast: Improved tracer clearance in the prostate bed. Nuklearmedizin - NuclearMedicine. 61(5). 394–401. 4 indexed citations
5.
Helgeland, Lars, et al.. (2022). Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. Current Oncology. 29(4). 2193–2198.
6.
Søreide, Jon Arne, Jan Terje Kvaløy, Oddvar M. Sandvik, et al.. (2021). The overriding role of surgery and tumor grade for long‐term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population‐based cohort study. Cancer Reports. 5(2). e1462–e1462. 6 indexed citations
7.
Haslerud, Torjan, et al.. (2017). E-learning for medical imaging specialists: introducing blended learning in a nuclear medicine specialist course. SHILAP Revista de lepidopterología. 6(7). 1114176693–1114176693. 9 indexed citations
8.
Sabet, Amir, Torjan Haslerud, Amin Sabet, et al.. (2015). Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine. European Journal of Nuclear Medicine and Molecular Imaging. 42(8). 1238–1246. 82 indexed citations
9.
Sabet, Amir, Charlotte J. Yong‐Hing, Torjan Haslerud, et al.. (2014). Kann die Peptid-Radiorezeptortherapie bei diffuser Knochenmetastasierung noch sicher angewendet werden?. Nuklearmedizin - NuclearMedicine. 53(2). 54–59. 11 indexed citations
10.
Sabet, Amir, Charlotte J. Yong‐Hing, Torjan Haslerud, et al.. (2014). Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?. Nuklearmedizin - NuclearMedicine. 53(2). 54–59. 21 indexed citations
11.
Ezziddin, Samer, Torjan Haslerud, Karin Mayer, et al.. (2014). Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 41(5). 925–933. 148 indexed citations
12.
Sabet, Amir, Ulrich‐Frank Pape, Torjan Haslerud, et al.. (2013). Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. European Journal of Nuclear Medicine and Molecular Imaging. 41(3). 505–510. 69 indexed citations
13.
Haslerud, Torjan, K. Reichmann, Carsten H. Meyer, et al.. (2013). Residual activity after radioembolization of liver tumours with 90Y resin microspheres. Nuklearmedizin - NuclearMedicine. 53(3). 95–98. 9 indexed citations
14.
Doğan, Ahmet, et al.. (2013). Liver and lymph node metastases of prostate cancer visualized on post-therapy imaging after treatment with 188Re-HEDP. Revista Española de Medicina Nuclear e Imagen Molecular. 33(1). 58–59. 1 indexed citations
15.
Sabet, Amir, Torjan Haslerud, Ulrich‐Frank Pape, et al.. (2013). Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 41(2). 205–210. 77 indexed citations
16.
Sabet, Amir, Torjan Haslerud, Amin Sabet, et al.. (2013). Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.. PubMed. 3(5). 437–45. 24 indexed citations
17.
Ezziddin, Samer, Carsten Meyer, Torjan Haslerud, et al.. (2012). 90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine. 53(11). 1663–1669. 58 indexed citations
18.
Ahmadzadehfar, Hojjat, Markus Möhlenbruch, Amir Sabet, et al.. (2011). Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with 99mTc-MAA accumulation in the anterior abdominal wall?. European Journal of Nuclear Medicine and Molecular Imaging. 38(8). 1477–1484. 25 indexed citations
19.
Ahmadzadehfar, Hojjat, Amir Sabet, Kai Wilhelm, et al.. (2011). The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. European Journal of Nuclear Medicine and Molecular Imaging. 39(2). 309–315. 39 indexed citations
20.
Sabet, Amir, Hojjat Ahmadzadehfar, Torjan Haslerud, et al.. (2011). Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization. Journal of Nuclear Medicine. 52(7). 1063–1067. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beth Chasen Breakdown of academic impact, for papers by Maria Rinzivillo Breakdown of academic impact, for papers by Marianne E. Pavel Breakdown of academic impact, for papers by Claudia Brogsitter Breakdown of academic impact, for papers by Ana L. Keppke Breakdown of academic impact, for papers by Nalan Alan Selçuk Breakdown of academic impact, for papers by Pablo Mínguez Gabiña Breakdown of academic impact, for papers by Jan-Paul Esser Breakdown of academic impact, for papers by Jutta Kappes Breakdown of academic impact, for papers by M. Ciresa
Rankless by CCL
2026